Results 161 to 170 of about 1,516,776 (324)

Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan, John R. Mills, Paulina Vargas, Naveen K. Paramasivan, Connie E. Lesnick, Eati Basal, Surendra Dasari, James P. Fryer, Shannon R. Hinson, Joseph Laporta, Amy Espinal, Dennis Fitzgerald, Carolina Garcia, Anna E. Morenkova, Paola Pergami, Anna Shah, Andrew Knight, Reghann LaFrance Corey, Vanda A. Lennon, Anastasia Zekeridou, Sean J. Pittock, Divyanshu Dubey, Andrew McKeon   +22 more
wiley   +1 more source

Cluster Analysis for the Selection of Potential Discriminatory Variables and the Identification of Subgroups in Archaeometry

, 2022
Pedro A. López‐García, Denisse L. Argote   +1 more
openalex   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Subgroup analysis in RAISE

, 2016
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine.
Obermannová, R., Van Cutsem, E., Yoshino, Takayuki, Bodoky, G., Prausová, J., García-Carbonero, Rocío, Ciuleanu, Tudor Eliade, Garcia Alfonso, P., Portnoy, D., Cohn, A. L., Yamazaki, K., Clingan, P., Lonardi, Sara, Kim, T. W., Yang, L., Nasroulah, F., Tabernero, Josep, Universitat Autònoma de Barcelona   +17 more
openaire   +1 more source

Brief Intervention for Daily Marijuana Users Identified by Screening in Primary Care: A Subgroup Analysis of the ASPIRE Randomized Clinical Trial

, 2015
Daniel Fuster, Debbie M. Cheng, Na Wang, Judith Bernstein, Tibor P. Palfai, Daniel P. Alford, Jeffrey H. Samet, Richard Saitz   +7 more
openalex   +2 more sources

<b>ToPP:</b> <b>T</b>umor <b>o</b>nline <b>P</b>rognostic Analysis <b>P</b>latform for Prognostic Feature Selection and Clinical Patient Subgroup Selection

, 2021
Jian Ouyang, Guangrong Qin, Zhenhao Liu, Xingxing Jian, Tieliu Shi, Lu Xie   +5 more
openalex   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Subgroup analysis of the cardiovascular disease incidence according to the quartiles of neutrophil count.

Kuang-Chung Wang (7022570), Chu-Lin Lin (21261821), Chun-Chieh Lin (491836), Yun-Tzu Lee (21261824), Le-Yin Hsu (195794), Kuo-Liong Chien (73583), Tzu-Lin Yeh (6664154)   +6 more
openalex   +1 more source

Changes in Immune‐Inflammation Status and Acute Ischemic Stroke Prognosis in Prospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Inflammation is a critical risk factor for poor outcomes in cerebral infarction. Prior studies focused primarily on baseline inflammation status, neglecting dynamic longitudinal changes. We try to investigate the association between immune‐inflammation status alterations and stroke prognosis, and evaluated three systemic biomarkers'
Songfang Chen, Wenting Huang, Yitian Liu, Xuan Chen, Buyu Ke, Qian Shen, Hanyu Cai, Jing Sun, Yan Li, Yungang Cao, Beilei Hu, Keyang Chen   +11 more
wiley   +1 more source

Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). [PDF]

Endocr Relat Cancer
Strosberg JR, Zemla T, Geyer S, Pulsipher S, Ou FS, Behr S, Raj N, Vijayvergia N, Dasari A, O'Reilly EM, Meyerhardt JA, Wolin EM, Halfdanarson TR, Chan JA.   +13 more
europepmc   +1 more source